The Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Men with Androgenetic Alopecia: a Systematic Review and Meta-analysis

Overview

Journal Clin Interv Aging

Publisher Dove Medical Press

Specialty Geriatrics

Date 2019 Mar 14

PMID 30863034

Citations 23

Authors

Zhongbao Zhou

Shiqiang Song

Zhenli Gao

Jitao Wu

Jiajia Ma

Yuanshan Cui

Affiliations

Soon will be listed here.

Abstract

Aim: We performed a meta-analysis to evaluate the efficacy and safety of dutasteride and finasteride in treating men with androgenetic alopecia (AGA) during a 24-week treatment cycle.

Methods: Randomized controlled trials of dutasteride and finasteride for treating AGA were searched using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The data were calculated using Rev Man v5.3.0. The reference lists of retrieved studies were also investigated.

Results: Three articles including 576 participants which compared dutasteride with finasteride were selected for our analysis. The mean change in total hair count (mean difference [MD], 28.57; 95% CI, 18.75-38.39; <0.00001), investigator's assessment of global photographs for the vertex (MD, 0.68; 95% CI, 0.13-1.23; =0.02) and frontal (MD, 0.63; 95% CI, 0.13-1.13; =0.01) views, panel global photographic assessment for the vertex (MD, 0.17; 95% CI, 0.09-0.24; <0.00001) and frontal (MD, 0.25; 95% CI, 0.18-0.31; <0.00001) views, and subjects' assessment (MD, 0.56; 95% CI, 0.18-0.94; =0.003) suggested that dutasteride provided a better efficacy in treating men with AGA compared with finasteride. With regard to the assessment of safety, altered libido (=0.54), erectile dysfunction (=0.07), and ejaculation disorders (=0.58), dutasteride did not show a significant difference compared with finasteride.

Conclusion: Dutasteride seems to provide a better efficacy compared with finasteride in treating AGA. The two drugs appear to show similar rates of adverse reactions, especially in sexual dysfunction.

Citing Articles

Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation.

Johnson H, Huang D, Clift A, Bersch-Ferreira A, Guimaraes G Cureus. 2025; 17(1):e77549.

PMID: 39958004 PMC: 11829753. DOI: 10.7759/cureus.77549.

Comparative study between fractional CO2 laser alone versus fractional CO2 laser combined with topical dutasteride in treatment of male androgenic alopecia.

Galal S, Ali M, A HafizHala H Lasers Med Sci. 2025; 40(1):16.

PMID: 39794606 PMC: 11723884. DOI: 10.1007/s10103-024-04269-8.

Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review.

Almudimeegh A, AlMutairi H, AlTassan F, AlQuraishi Y, Nabil Nagshabandi K Dermatol Reports. 2025; 16(4):9909.

PMID: 39749123 PMC: 11694415. DOI: 10.4081/dr.2024.9909.

Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors.

Rohan T, Turchetta G, Yang S Arch Dermatol Res. 2024; 317(1):46.

PMID: 39589522 DOI: 10.1007/s00403-024-03542-8.

Can Plant Extracts Help Prevent Hair Loss or Promote Hair Growth? A Review Comparing Their Therapeutic Efficacies, Phytochemical Components, and Modulatory Targets.

Choi J, Boo M, Boo Y Molecules. 2024; 29(10).

PMID: 38792149 PMC: 11124163. DOI: 10.3390/molecules29102288.

References

Tang P, Chia H, Cheong L, Koh D . A community study of male androgenetic alopecia in Bishan, Singapore. Singapore Med J. 2000; 41(5):202-5. View

. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002; 12(1):38-49. View

Roehrborn C, Boyle P, Nickel J, Hoefner K, Andriole G . Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60(3):434-41. DOI: 10.1016/s0090-4295(02)01905-2. View

Clark R, Hermann D, Cunningham G, Wilson T, Morrill B, Hobbs S . Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89(5):2179-84. DOI: 10.1210/jc.2003-030330. View

Debruyne F, Barkin J, Van Erps P, Reis M, Tammela T, Roehrborn C . Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004; 46(4):488-94. DOI: 10.1016/j.eururo.2004.05.008. View

Cash T . The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992; 26(6):926-31. DOI: 10.1016/0190-9622(92)70134-2. View

Price V, Menefee E, Sanchez M, Kaufman K . Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol. 2006; 55(1):71-4. DOI: 10.1016/j.jaad.2005.07.001. View

Olsen E, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis M . The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006; 55(6):1014-23. DOI: 10.1016/j.jaad.2006.05.007. View

Su L, Chen T . Association of androgenetic alopecia with smoking and its prevalence among Asian men: a community-based survey. Arch Dermatol. 2007; 143(11):1401-6. DOI: 10.1001/archderm.143.11.1401. View

10.

Yazdabadi A, Magee J, Harrison S, Sinclair R . The Ludwig pattern of androgenetic alopecia is due to a hierarchy of androgen sensitivity within follicular units that leads to selective miniaturization and a reduction in the number of terminal hairs per follicular unit. Br J Dermatol. 2008; 159(6):1300-2. DOI: 10.1111/j.1365-2133.2008.08820.x. View

11.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

12.

Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F . Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362(13):1192-202. DOI: 10.1056/NEJMoa0908127. View

13.

Inui S, Itami S . Molecular basis of androgenetic alopecia: From androgen to paracrine mediators through dermal papilla. J Dermatol Sci. 2010; 61(1):1-6. DOI: 10.1016/j.jdermsci.2010.10.015. View

14.

Pinsky M, Gur S, Tracey A, Harbin A, Hellstrom W . The effects of chronic 5-alpha-reductase inhibitor (dutasteride) treatment on rat erectile function. J Sex Med. 2011; 8(11):3066-74. DOI: 10.1111/j.1743-6109.2011.02425.x. View

15.

Sato A, Takeda A . Evaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopecia. J Dermatol. 2011; 39(1):27-32. DOI: 10.1111/j.1346-8138.2011.01378.x. View

16.

Han S, Byun J, Lee W, Kang H, Kye Y, Kim K . Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012; 24(3):311-8. PMC: 3412240. DOI: 10.5021/ad.2012.24.3.311. View

17.

Harcha W, Barboza Martinez J, Tsai T, Katsuoka K, Kawashima M, Tsuboi R . A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014; 70(3):489-498.e3. DOI: 10.1016/j.jaad.2013.10.049. View

18.

Haddad A, Jabbour M, Bulbul M . Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review. Arab J Urol. 2015; 13(3):155-61. PMC: 4563010. DOI: 10.1016/j.aju.2015.06.004. View

19.

Mysore V, Shashikumar B . Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016; 82(2):128-34. DOI: 10.4103/0378-6323.177432. View

20.

Wolff H, Fischer T, Blume-Peytavi U . The Diagnosis and Treatment of Hair and Scalp Diseases. Dtsch Arztebl Int. 2016; 113(21):377-86. PMC: 4908932. DOI: 10.3238/arztebl.2016.0377. View